Breast cancer

FDA Approves Seno Medical’s Ground-Breaking Breast Cancer Diagnostic Technology

Tuesday, January 19, 2021 - 3:45pm

San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions.

Key Points: 
  • San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions.
  • The companys Imagio Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may - or may not - require more invasive diagnostic evaluation.
  • The companys OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
  • Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapy

Tuesday, January 19, 2021 - 2:30pm

OCEANSIDE, Calif., Jan. 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs cellular immunotherapy.

Key Points: 
  • OCEANSIDE, Calif., Jan. 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs cellular immunotherapy.
  • In a series of experiments, it was demonstrated that StemVacs administration resulted in a) regression of established breast cancer in mice; b) that regression was dependent on natural killer cells, and c) that immunity to breast cancer could be transferred by CD4 T cells to nave mice.
  • "Therapeutic Solutions International is a 'science-driven' organization," said Timothy Dixon, President and CEO.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

United Breast Cancer Foundation Shares PSA to Spread the Love and Drive Out Breast Cancer

Tuesday, January 19, 2021 - 2:00pm

HUNTINGTON, N.Y., Jan. 19, 2021 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF), a GuideStar Platinum rated charity, launched the Public Service Announcement, " Spread the Love and Drive Out Breast Cancer " with a Call to Action requesting vehicle donations to support breast cancer patients and families.

Key Points: 
  • HUNTINGTON, N.Y., Jan. 19, 2021 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF), a GuideStar Platinum rated charity, launched the Public Service Announcement, " Spread the Love and Drive Out Breast Cancer " with a Call to Action requesting vehicle donations to support breast cancer patients and families.
  • By donating a vehicle to UBCF, you're helping sustain UBCF's mission to make a positive difference in the lives of those affected by breast cancer.
  • Proceeds from the sale of donated vehicles fund innovative breast cancer education, screening, treatment and support services nationwide.
  • Breast cancer is the leading cause of cancer death among women aged 40-50 years in the U.S.

Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibit

Tuesday, January 19, 2021 - 1:30pm

In the Nature Medicine publication, Dr. Hickey and colleagues provide scientific evidence supporting a new discovery in breast cancer demonstrating that the androgen receptor acts like a tumor suppressor.

Key Points: 
  • In the Nature Medicine publication, Dr. Hickey and colleagues provide scientific evidence supporting a new discovery in breast cancer demonstrating that the androgen receptor acts like a tumor suppressor.
  • Further, enobosarm, by activating the androgen receptor, has demonstrated antitumor activity in both estrogen receptor targeted endocrine therapy resistant and CDK4/6 inhibitor resistant metastatic human breast cancer models.
  • This study clears up the confusion in the scientific field regarding the role that the androgen receptor is playing in ER+ breast cancer.
  • The Veru breast cancer pipeline includes enobosarm for hormone sensitive metastatic ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer.

Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy

Tuesday, January 19, 2021 - 1:00pm

The National Comprehensive Cancer Network (NCCN) Panel expanded its clinical practice guideline for breast cancer by recognizing Breast Cancer Index as the only gene expression assay for prediction of benefit from extended endocrine therapy when considering adjuvant systemic therapy.

Key Points: 
  • The National Comprehensive Cancer Network (NCCN) Panel expanded its clinical practice guideline for breast cancer by recognizing Breast Cancer Index as the only gene expression assay for prediction of benefit from extended endocrine therapy when considering adjuvant systemic therapy.
  • Breast Cancer Index is the only test of its kind recommended to predict benefit from extended endocrine therapy for early-stage hormone receptor positive breast cancer.
  • Don Hardison, Biotheranostics President and CEO adds, We are thrilled that the NCCN has recognized Breast Cancer Index as the only biomarker to inform the decision of extended endocrine therapy.
  • Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer.

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Tuesday, January 19, 2021 - 12:05pm

Myriad estimates there are more than 78,000 cases of prostate cancer and 40,000 cases of pancreatic cancer per year in Japan.

Key Points: 
  • Myriad estimates there are more than 78,000 cases of prostate cancer and 40,000 cases of pancreatic cancer per year in Japan.
  • With the reimbursement decision, approximately 20,000 patients in Japan will now qualify to receive genetic testing.
  • Group Holdings, Inc. to expand the commercialization of the BRACAnalysis Diagnostic System in Japan.
  • BRACAnalysis is a diagnostic system that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.

Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

Friday, January 15, 2021 - 1:03pm

The last drug to be approved in the first-line metastatic pancreatic cancer setting is Abraxane (nab-paclitaxel).

Key Points: 
  • The last drug to be approved in the first-line metastatic pancreatic cancer setting is Abraxane (nab-paclitaxel).
  • The initial response rate is promising, and thus far there has not been significant additive toxicity from AB680 to chemotherapy.
  • AB680 is currently in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer.
  • AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel.

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Thursday, January 14, 2021 - 9:30pm

The trial will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Key Points: 
  • The trial will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
  • FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer.
  • Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas.
  • Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer.

City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adults

Thursday, January 14, 2021 - 9:00pm

(Photo credit: City of Hope)

Key Points: 
  • (Photo credit: City of Hope)
    This first-of-its-kind risk assessment tool called the Cancer and Aging Research Group-Breast Cancer (CARG-BC) Score helps oncologists make personalized treatment recommendations.
  • Oncologists can discuss the score and its significance with early-stage breast cancer patients age 65 or older.
  • Though chemotherapy is an effective way to treat early-stage breast cancer, it also carries a risk of side effects.
  • As a next step, the researchers will look to improve the chemotherapy toxicity risk assessment tool with more biological markers.

NeoDynamics will be granted another European patent for its pulse biopsy tools

Thursday, January 14, 2021 - 7:41am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".